P-PSMA-101

November 5, 2020November 5, 2020

Hold Lifted on Phase 1 Trial Testing P-PSMA-101 CAR T-cell Therapy in mCRPC

News

A Phase 1 trial evaluating Poseida Therapeutics’ autologous CAR T-cell therapy P-PSMA-101 for metastatic castration-resistant prostate cancer (mCRPC) is resuming immediately, after its clinical hold was lifted. The U.S. Food ... Read more

November 13, 2017

P-PSMA-101 Generates Long-Lasting Response to Prostate Cancer, Mouse Study Shows

News

Poseida Therapeutics’ P-PSMA-101 eliminated prostate cancer in all mice that were treated in a study and prevented it from returning in two-thirds, researchers reported. The long-lasting nature of the therapy ... Read more

October 6, 2017

Poseida’s CAR T-cell Therapy Eradicates Previously Incurable Prostate Cancer in Mice

News

Poseida Therapeutics’ CAR T-cell therapy P-PSMA-101 eradicated a previously incurable type of human prostate cancer implanted in mice, the company reported. Another CAR T-cell therapy that has reached doctor’s offices ... Read more